Urologie pro praxi 3/2021
The actual pharmacotherapy benign hyperplasia according to EAU Guidelines
Pharmacological treatment is the basis for conservative treatment of lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH). Currently, pharmacological treatment is based on α1-blockers, 5α-reductase inhibitors, muscarinic receptor antagonists, phosphodiesterase 5 inhibitors, beta-3 adrenoceptor agonists and a combination of some of them. In indicated cases, phytopharmaceuticals, most commonly containing Serenoa repens, may be used in patients with minor LUTS.
Keywords: benign prostatic hyperplasia, α1-blockers, 5α-reductase inhibitors, antagonists, muscarinic receptors, phosphodiesterase 5 inhibitors, beta-3 adrenoceptor, agonists, Serenoa repens.
